Impact of PNPLA3 polymorphisms on the development of hepatocellular carcinoma in patients with chronic hepatitis C virus infection

Hepatology Research

Volumn 44, Issue 10, 2014, Pages E137-E144

  Sato, Masaya ^a   Kato, Naoya ^b   Tateishi, Ryosuke ^a   Muroyama, Ryosuke ^b   Kowatari, Norie ^b   Li, Wenwen ^b   Goto, Kaku ^b   Otsuka, Motoyuki ^a   Shiina, Shuichiro ^a   Yoshida, Haruhiko ^a   Omata, Masao ^c   Koike, Kazuhiko ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c Yamanashi Prefectural Hospital Organization   (Japan)

Author keywords

Fibrosis; Hepatocarcinogenesis; Risk allele; Rs738409; Steatosis

Indexed keywords

ASPARTATE AMINOTRANSFERASE;

ADULT; AGED; ARTICLE; CHRONIC HEPATITIS C; FATTY LIVER; FEMALE; GENE; GENETIC ASSOCIATION; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 2; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PNPLA3 GENE; PROTHROMBIN TIME; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84907877530     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12258     Document Type: Article

References (45)

1. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5: 558-567.
2. Barrera JM, Bruguera M, Ercilla MG etal. Persistent hepatitis C viremia after acute self-limiting posttransfusion hepatitis C. Hepatology 1995; 21: 639-644.
3. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349: 825-832.
4. Hourigan LF, Macdonald GA, Purdie D etal. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology 1999; 29: 1215-1219.
5. Powell EE, Edwards-Smith CJ, Hay JL etal. Host genetic factors influence disease progression in chronic hepatitis C. Hepatology 2000; 31: 828-833.
6. Massard J, Ratziu V, Thabut D etal. Natural history and predictors of disease severity in chronic hepatitis C. J Hepatol 2006; 44: S19-24.
7. Bochud PY, Cai T, Overbeck K etal. Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. J Hepatol 2009; 51: 655-666.
8. De Nicola S, Aghemo A, Rumi MG, Colombo M. HCV genotype 3: an independent predictor of fibrosis progression in chronic hepatitis C. J Hepatol 2009; 51: 964-966.
9. Ohki T, Tateishi R, Sato T etal. Obesity is an independent risk factor for hepatocellular carcinoma development in chronic hepatitis C patients. Clin Gastroenterol Hepatol 2008; 6: 459-464.
10. Thursz M, Yallop R, Goldin R, Trepo C, Thomas HC. Influence of MHC class II genotype on outcome of infection with hepatitis C virus. The HENCORE group. Hepatitis C European Network for Cooperative Research. Lancet 1999; 354: 2119-2124.
11. Pradat P, Tillmann HL, Sauleda S etal. Long-term follow-up of the hepatitis C HENCORE cohort: response to therapy and occurrence of liver-related complications. J Viral Hepat 2007; 14: 556-563.
12. Kato N, Ji G, Wang Y etal. Large-scale search of single nucleotide polymorphisms for hepatocellular carcinoma susceptibility genes in patients with hepatitis C. Hepatology 2005; 42: 846-853.
13. Kumar V, Kato N, Urabe Y etal. Genome-wide association study identifies a susceptibility locus for HCV-induced hepatocellular carcinoma. Nat Genet 2011; 43: 455-458.
14. Miki D, Ochi H, Hayes CN etal. Variation in the DEPDC5 locus is associated with progression to hepatocellular carcinoma in chronic hepatitis C virus carriers. Nat Genet 2011; 43: 797-800.
15. Argo CK, Caldwell SH. Epidemiology and natural history of non-alcoholic steatohepatitis. Clin Liver Dis 2009; 13: 511-531.
16. Bedogni G, Bellentani S. Fatty liver: how frequent is it and why? Ann Hepatol 2004; 3: 63-65.
17. Lazo M, Clark JM. The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin Liver Dis 2008; 28: 339-350.
18. Everhart JE, Bambha KM. Fatty liver: think globally. Hepatology 2010; 51: 1491-1493.
19. Bedossa P, Moucari R, Chelbi E etal. Evidence for a role of nonalcoholic steatohepatitis in hepatitis C: a prospective study. Hepatology 2007; 46: 380-387.
20. Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001; 33: 1358-1364.
21. Koike K, Tsutsumi T, Yotsuyanagi H, Moriya K. Lipid metabolism and liver disease in hepatitis C viral infection. Oncology 2010; 78 (Suppl 1): 24-30.
22. Jenkins CM, Mancuso DJ, Yan W, Sims HF, Gibson B, Gross RW. Identification, cloning, expression, and purification of three novel human calcium-independent phospholipase A2 family members possessing triacylglycerol lipase and acylglycerol transacylase activities. J Biol Chem 2004; 279: 48968-48975.
23. Romeo S, Kozlitina J, Xing C etal. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008; 40: 1461-1465.
24. Kawaguchi T, Sumida Y, Umemura A etal. Genetic polymorphisms of the human PNPLA3 gene are strongly associated with severity of non-alcoholic fatty liver disease in Japanese. PLoS ONE 2012; 7: e38322.
25. Sookoian S, Pirola CJ. Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology 2011; 53: 1883-1894.
26. Huang Y, Cohen JC, Hobbs HH. Expression and characterization of a PNPLA3 protein isoform (I148M) associated with nonalcoholic fatty liver disease. J Biol Chem 2011; 286: 37085-37093.
27. Chen W, Chang B, Li L, Chan L. Patatin-like phospholipase domain-containing 3/adiponutrin deficiency in mice is not associated with fatty liver disease. Hepatology 2010; 52: 1134-1142.
28. Li JZ, Huang Y, Karaman R etal. Chronic overexpression of PNPLA3I148M in mouse liver causes hepatic steatosis. J Clin Invest 2012; 122: 4130-4144.
29. Kollerits B, Coassin S, Kiechl S etal. A common variant in the adiponutrin gene influences liver enzyme values. J Med Genet 2010; 47: 116-119.
30. Dunn W, Zeng Z, O'Neil M etal. The interaction of rs738409, obesity, and alcohol: a population-based autopsy study. Am J Gastroenterol 2012; 107: 1668-1674.
31. Valenti L, Al-Serri A, Daly AK etal. Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 2010; 51: 1209-1217.
32. Rotman Y, Koh C, Zmuda JM, Kleiner DE, Liang TJ. The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease. Hepatology 2010; 52: 894-903.
33. Tian C, Stokowski RP, Kershenobich D, Ballinger DG, Hinds DA. Variant in PNPLA3 is associated with alcoholic liver disease. Nat Genet 2010; 42: 21-23.
34. Nischalke HD, Berger C, Luda C etal. The PNPLA3 rs738409 148M/M genotype is a risk factor for liver cancer in alcoholic cirrhosis but shows no or weak association in hepatitis C cirrhosis. PLoS ONE 2011; 6: e27087.
35. Trepo E, Pradat P, Potthoff A etal. Impact of patatin-like phospholipase-3 (rs738409 C>G) polymorphism on fibrosis progression and steatosis in chronic hepatitis C. Hepatology 2011; 54: 60-69.
36. Valenti L, Rumi M, Galmozzi E etal. Patatin-like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C. Hepatology 2011; 53: 791-799.
37. Guyot E, Sutton A, Rufat P etal. PNPLA3 rs738409, hepatocellular carcinoma occurrence and risk model prediction in patients with cirrhosis. J Hepatol 2013; 58: 312-318.
38. Edmondson HA, Steiner PE. Primary carcinoma of the liver: a study of 100 cases among 48, 900 necropsies. Cancer 1954; 7: 462-503.
39. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology 1994; 20: 15-20.
40. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24: 289-293.
41. Krawczyk M, Grunhage F, Zimmer V, Lammert F. Variant adiponutrin (PNPLA3) represents a common fibrosis risk gene: non-invasive elastography-based study in chronic liver disease. J Hepatol 2011; 55: 299-306.
42. Ohata K, Hamasaki K, Toriyama K etal. Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection. Cancer 2003; 97: 3036-3043.
43. Falleti E, Fabris C, Cmet S etal. PNPLA3 rs738409C/G polymorphism in cirrhosis: relationship with the aetiology of liver disease and hepatocellular carcinoma occurrence. Liver Int 2011; 31: 1137-1143.
44. Kasahara A, Hayashi N, Mochizuki K etal. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group. Hepatology 1998; 27: 1394-1402.
45. Ikeda K, Saitoh S, Arase Y etal. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: a long-term observation study of 1, 643 patients using statistical bias correction with proportional hazard analysis. Hepatology 1999; 29: 1124-1130.